Acute Kidney Injury Treatment Market (Treatment: Dialysis and Supportive Care; and End-user: Hospitals, Ambulatory Surgical Centers, and Others)- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2022-2030

According to Nova one advisor, the global Acute Kidney Injury Treatment market was valued at USD 2.5 billion in 2022 and it is expected to hit around USD 4.18 billion by 2030 with a CAGR of 7.5% during the forecast period 2022 to 2030.

Acute kidney injury (AKI) is a sudden episode of kidney failure/damage that can range from minor loss of kidney functions to complete kidney failure. Diarrhea, feeling sick or being sick, dehydration, drowsiness, and confusion are some of the common symptoms of acute kidney injuries.

Treatment for kidney injuries primarily depends on the cause and extent of the injury. Experimental treatments for the management of AKIs primarily comprise vasoactive peptides, growth-factors, endothelin inhibitors, adhesion molecules, and bio-artificial kidneys. Aminophylline has also been used experimentally for prophylaxis, specifically against renal failure (RF).

Report Scope of the Acute Kidney Injury Treatment Market

 Increase in Geriatric Population and Rise in Incidence of Acute Kidney Injury

The geriatric population has increased in the past few years, especially in developed countries such as the U.S., Japan, and most countries in Western Europe. These countries have high geriatric population vis-à-vis their developing counterparts. This can be ascribed to the improvement in health care infrastructure, favorable reimbursement policies, and advancements in health care facilities. Access to multiple diagnostic and treatment services has improved, specifically in developed countries. This has increased the life expectancy of the population.

Studies indicate that a majority (60% to 70%) of the elderly population is susceptible to acute kidney injury. Increase in geriatric population leads to high rate of ailments. This, in turn, is likely to augment the demand for acute kidney injury medications across the globe in the near future.

Around 13.3 million people across the world are estimated to be affected by acute kidney injury. The patient population is expected to rise substantially in the next few decades. Increase in incidence rate of acute kidney injury is creating a significant socioeconomic impact across the globe.

Surge in Number of Critical Care Admissions

According to an independent research, multiple system organ failure (MSOF) and other comorbidities contribute to high mortality rate among intensive care unit (ICU) patients. However, the mortality rate of AKI stands at 50% to 80% in ICU patients. Acute kidney injury (AKI) often occurs in intensive care units (ICUs), thus leading to high expenditure along with adverse clinical outcomes.

AKI is primarily associated with incomplete kidney recovery and increase in mortality and cost. This is likely to lead to a surge in demand for effective acute kidney failure treatment, which is projected to accelerate acute kidney injury treatment market progress.

Lifesaving Treatment Propelling Dialysis Segment

In terms of treatment, the dialysis segment accounted for major market share in 2021. Dialysis facilitates the survival of critically ill patients with AKIs. The total number of dialysis service centers has increased across the globe. This is anticipated to drive the dialysis segment during the forecast period.

According to the United States Renal Data system (USRDS), the U.S. had more than 7,500 dialysis centers in 2021. Governments of developing countries are setting up new dialysis centers and improving the existing ones. In November 2022, Southlake Biotech, an innovative biotech-firm, announced that it will receive US$ 33.0 Mn in financing to advance its portfolio of kidney disease treatments.

Growth in Incidence Bolstering Pre-renal Acute Kidney Injury Segment

Pre-renal acute kidney injuries account for 55% to 65% of cases with acute kidney injury (AKIs). Introduction of novel drugs and increase in investment in research and innovation are likely to augment the pre-renal acute kidney injury segment during the forecast period.

Regional Outlook of Acute Kidney Injury Treatment Market

North America accounted for around 43.0% share of the global industry in 2021. Increase in geriatric population, rise in acute kidney injury patient pool, promising clinical pipeline, and development of advanced & efficient products are fueling the North America market expansion. Rise in number of key players; increase in acquisitions, mergers, and collaborations; government approval for new products; and surge in adoption of advanced products are boosting business outlook in the region.

Asia Pacific is projected to be a rapidly growing region for AKI treatment during the forecast period. Increase in geriatric population; rise in prevalence of chronic diseases, which are high risk factors for acute kidney injury; growth in urbanization; and surge in critical care admissions are boosting the region's market statistics. Government initiatives in the healthcare sector, increase in investment in R&D activities, and rise in presence of global players are fueling the demand for AKI treatment in Asia Pacific.

Analysis of Key Players

The acute kidney injury treatment market is highly consolidated, with the presence of small number of dominant players. Companies are engaging in strategic alliances to increase revenue and market share. Players are also adopting strategies such as product line expansion and acquisitions & mergers to broaden their business footprint.

Some of the prominent players in the Acute Kidney Injury Treatment Market include:

• Angion Biomedica Corp.
• AM-Pharma
• Quark Pharmaceuticals, Inc.
• Baxter International, Inc.
• Fresenius Medical Care AG & Co. KGaA.
• B. Braun Melsungen AG
• Asahi Kasei Medical Co., Ltd.
• LG Chem

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Acute Kidney Injury Treatment market

• Treatment
• Dialysis
• Supportive Care
• Type
• Pre-renal Acute Kidney Injury
• Intrinsic Renal Acute Kidney Injury
• Post-renal Acute Kidney Injury
• End-user
• Hospitals
• Ambulatory Surgical Centers
• Others

By Geography

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa (MEA)

Key Benefits for Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the global Acute Kidney Injury Treatment industry analysis from 2022 to 2030 to identify the prevailing Acute Kidney Injury Treatment industry opportunity.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the global Acute Kidney Injury Treatment industry segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global Acute Kidney Injury Treatment industry trends, key players, market segments, application areas, and market growth strategies.